RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs by Mylène Gerritsen, Guoqiang Yi,

Slides:



Advertisements
Similar presentations
by Ayten Kandilci, and Gerard C. Grosveld
Advertisements

Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples by Keiki Kumano, Shunya Arai, Masataka Hosoi, Kazuki.
by Benjamin J. Frisch, John M. Ashton, Lianping Xing, Michael W
HOXA9 promotes hematopoietic commitment of human embryonic stem cells
Dynamic epigenetic enhancer signatures reveal key transcription factors associated with monocytic differentiation states by Thu-Hang Pham, Christopher.
Repression of BMI1 in normal and leukemic human CD34+ cells impairs self-renewal and induces apoptosis by Aleksandra Rizo, Sandra Olthof, Lina Han, Edo.
Volume 14, Issue 2, Pages (January 2016)
Volume 17, Issue 12, Pages (December 2016)
EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression
Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation  Melanie Wurm, John Kowalski, Dirk Heckl, Xiao-Bing.
Emergence of muscle and neural hematopoiesis in humans
Bone morphogenetic protein 4 induces efficient hematopoietic differentiation of rhesus monkey embryonic stem cells in vitro by Fei Li, Shijiang Lu, Loyda.
MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing by Corina Schneidawind, Johan Jeong,
by Anupama Narla, Shilpee Dutt, J
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features by Maria E. Figueroa, Bas J.
Expression profiling of snoRNAs in normal hematopoiesis and AML
Volume 11, Issue 2, Pages (August 2012)
by Holger Weishaupt, Mikael Sigvardsson, and Joanne L. Attema
Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis by Catharina Wenk, Anne-Kathrin.
Regulation of Mammary Luminal Cell Fate and Tumorigenesis by p38α
Genome-Wide Analysis of PLT2 Binding to Target Genes.
Genome-wide analysis shows that Ldb1 controls essential hematopoietic genes/pathways in mouse early development and reveals novel players in hematopoiesis.
Lentiviral-mediated RNAi inhibition of Sbds in murine hematopoietic progenitors impairs their hematopoietic potential by Amy S. Rawls, Alyssa D. Gregory,
RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells by Takahiro Suzuki, Yuri Shimizu,
by Laura J. Norton, Alister P. W
by Kentson Lam, Alexander Muselman, Randal Du, Yuka Harada, Amanda G
by Hairui Su, Chiao-Wang Sun, Szu-Mam Liu, Xin He, Hao Hu, Kevin M
Volume 28, Issue 2, Pages (August 2015)
Volume 17, Issue 4, Pages (October 2015)
Dynamic change of transcription pausing through modulating NELF protein stability regulates granulocytic differentiation by Xiuli Liu, Aishwarya A. Gogate,
Aging Impairs Long-Term Hematopoietic Regeneration after Autologous Stem Cell Transplantation  Carolien M. Woolthuis, Niccoló Mariani, Rikst Nynke Verkaik-Schakel,
Induced pluripotent stem cell–based mapping of β-globin expression throughout human erythropoietic development by Kim Vanuytsel, Taylor Matte, Amy Leung,
Volume 4, Issue 2, Pages (February 2015)
Gpr171, a putative P2Y-like receptor, negatively regulates myeloid differentiation in murine hematopoietic progenitors  Lara Rossi, Roberto M. Lemoli,
Volume 10, Issue 2, Pages (February 2018)
Volume 33, Issue 6, Pages (December 2010)
Volume 23, Issue 1, Pages 9-22 (January 2013)
C/EBPα overrides epigenetic reprogramming by oncogenic transcription factors in acute myeloid leukemia by Justin Loke, Paulynn Suyin Chin, Peter Keane,
Volume 10, Issue 1, Pages (January 2018)
Figure 2. Ectopic expression of PLZF modulates H3K27ac at enhancer regions in myeloid cells. (A) Box plots showing ... Figure 2. Ectopic expression of.
by Nur-Taz Rahman, Vincent P. Schulz, Lin Wang, Patrick G
Volume 67, Issue 6, Pages e6 (September 2017)
CD16+ monocytes give rise to CD103+RALDH2+TCF4+ dendritic cells with unique transcriptional and immunological features by Vanessa Sue Wacleche, Amélie.
M1 and M2 macrophages differentially regulate hematopoietic stem cell self-renewal and ex vivo expansion by Yi Luo, Lijian Shao, Jianhui Chang, Wei Feng,
Volume 9, Issue 5, Pages (November 2017)
Volume 54, Issue 5, Pages (June 2014)
Deletion of the Scl +19 enhancer increases the blood stem cell compartment without affecting the formation of mature blood lineages  Dominik Spensberger,
Evolution of Alu Elements toward Enhancers
Application of small molecule CHIR99021 leads to the loss of hemangioblast progenitor and increased hematopoiesis of human pluripotent stem cells  Yekaterina.
Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice by Jacob T. Jackson, Ashley P.
Volume 35, Issue 2, Pages (August 2011)
Volume 17, Issue 8, Pages (November 2016)
Twist1 regulates embryonic hematopoietic differentiation through binding to Myb and Gata2 promoter regions by Kasem Kulkeaw, Tomoko Inoue, Tadafumi Iino,
Volume 20, Issue 13, Pages (September 2017)
C/EBPβ is a critical mediator of IFN-α–induced exhaustion of chronic myeloid leukemia stem cells by Asumi Yokota, Hideyo Hirai, Ryuichi Sato, Hiroko Adachi,
Volume 7, Issue 2, Pages (August 2010)
Kiran Batta, Magdalena Florkowska, Valerie Kouskoff, Georges Lacaud 
by Defne Bayik, Debra Tross, Lydia A
AZA treatment induces a distinct gene-expression pattern in stromal cells. AZA treatment induces a distinct gene-expression pattern in stromal cells. (A-C)
Proliferation of Aml1-excised immortalized BM cells is enhanced in vitro. Proliferation of Aml1-excised immortalized BM cells is enhanced in vitro. (A)
Volume 17, Issue 4, Pages (October 2015)
Volume 20, Issue 13, Pages (September 2017)
ChIP-seq for H3K4me and H3K27ac assigns potential enhancers to transcripts under control of HoxA9. ChIP-seq for H3K4me and H3K27ac assigns potential enhancers.
CD4+CLA+CD103+ T cells from human blood and skin share a transcriptional profile. CD4+CLA+CD103+ T cells from human blood and skin share a transcriptional.
Volume 12, Issue 2, Pages (February 2013)
The prostate cancer risk variant rs regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression.
Transcriptional and genomic targets of EN1 in TNBC cells.
Volume 14, Issue 6, Pages (February 2016)
Chromatin state mapping pinpoints PAX3–FOXO1 (P3F) in active enhancers
Fig. 2 Combined transcriptome profiling, ChIP-seq, and ATAC-seq analysis identifies 14 highly plausible direct targets of Runx. Combined transcriptome.
Presentation transcript:

RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs by Mylène Gerritsen, Guoqiang Yi, Esther Tijchon, Jorren Kuster, Jan Jacob Schuringa, Joost H. A. Martens, and Edo Vellenga BloodAdv Volume 3(3):320-332 February 12, 2019 © 2019 by The American Society of Hematology

Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology

RUNX1mut increases replating capacity. RUNX1mut increases replating capacity. (A) Schematic overview of RUNX1wt and RUNX1 S291fs300X mutant. (B) CFC and replating potential of RUNX1mut vs control. At the start, 500 cells were plated per dish in duplicates. Between days 10 to 14, the number of colonies were scored and all colonies were harvested. For each replating, 25 000 cells per dish were plated. Replating potential of control vs RUNX1mut in the CD14−/CD15− fraction (C) and replating potential of control vs RUNX1mut in the CD14+/CD15+ fraction (D). At the start, 500 cells were plated per dish in duplicates. Between days 10 and 14, the number of colonies were scored and colonies were harvested and stained for CD14 and CD15. In a new CFC, 25 000 CD14+ or CD15+ cells and 25 000 CD14−/CD15− cells were FACS sorted. After 10 to 14 days, this was repeated for another replating round. *P < .05; **P < .01. Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology

RUNX1mut-transduced CB CD34+ cells have increased growth potential, LTC-IC-frequency, and CD34+ maintenance. RUNX1mut-transduced CB CD34+cells have increased growth potential, LTC-IC-frequency, and CD34+maintenance. (A) Relative expansion in MS5 coculture of control vs RUNX1mut. Growth curve of MS5 coculture (5 weeks). After 5 weeks, the MS5 was replated (see supplemental Figure 2A for continued growth). (B) Marker expression analysis of adherent fraction of RUNX1mut cells in MS5 coculture after 10 weeks. Expansion of suspension fraction was very limited and did not allow for surface marker expression after 10 weeks. (C) Relative expansion in liquid culture over a course of several weeks in control vs RUNX1mut (n = 3). (D) Marker expression analysis of RUNX1mut cells in liquid culture after 10 weeks. (E) CD34+ expression of 3 CB control vs RUNX1mut cells in time. Each line represents a different culture. (F) LTC-IC frequency of control vs RUNX1mut cells. *P < .05. Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology

CEBPA expression is decreased in RUNX1mut cells. CEBPA expression is decreased in RUNX1mut cells. (A) CD114 expression of CB control vs RUNX1mut cells in time in cells cultured with G-CSF. (B) qRT-PCR analysis of CEBPA, an SPI1 expression in control vs RUNX1mut after ∼2 weeks of expansion in liquid culture medium. (C) Relative CEBPA expression in RUNX1wt vs RUNX1mut AMLs in the TCGA data set. AML1-ETO or inv(16) AMLs are excluded from this analysis. (D) Immature marker (CD34) and immature markers (CD14 and CD15) expression before and after 3 days of overexpression of CEBPA-ER induced by tamoxifen. (E) Percentage of mature and immature-appearing cells in RUNX1mut and RUNX1mut + CEBPA cells after 3 days of overexpression of CEBPA. Two hundred cells were score a rated mature or immature on the basis of their morphology. *P < .05; **P < .01; ***P < .001. Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology

iPSC differentiation is impaired when expressing RUNX1mut. iPSC differentiation is impaired when expressing RUNX1mut. (A) Time schedule of iPSC differentiation protocol and marker expression analysis. At the beginning of the hematological differentiation (blue arrow), doxycycline is added, inducing expression of RUNX1mut. Cell surface marker expression on CD34/CD45 was performed on different points (red arrows). (B) Example of marker analysis and a representable figure of CD34+/CD45+ and CD34−/CD45+ expression on different points during differentiation. (C) Marker analysis and a representable figure of CD15 and CD16 expression in control vs RUNX1mut-expressing iPSCs on day 17 of differentiation. (D) Log2 expression levels of CEBPA in control vs dox-induced iPS cells. Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology

The RUNX1mut gene program. The RUNX1mut gene program. (A) PCA plot using RNA-seq results of the indicated cell types. Hollow circle indicates RNA-seq data from published primary AMLs carrying RUNX1mut (https://leucegene.ca/research-development/). Normal cells are indicated within the blue circles. (B) Based on RNA-seq predicted average fraction of CD34+ cells, granulocytes, monocytes, and macrophages in RUNX1mut-expressing cells, using CIBERSORT. (C) Differential expression of monocytic and granulocytic signature genes in normal CD34 cells, RUNX1mut expressing CB cells, iPSC models, and primary AML cells. (D) Heat map of gene expression by k-means clustering in RUNX1mut-expressing CB, iPSC, and primary AML cells vs control CD34+ cells resulting in 4 main clusters. (E) Biological process enrichment for each of the 4 clusters identified in panel D. **P < .01; ***P < .001. ns, not significant. Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology

RUNX1 binding in model cells and primary AMLs RUNX1 binding in model cells and primary AMLs. (A) Heat map of RUNX1mut-binding sites in RUNX1mut-transduced CB cells, control and RUNX1mut-induced iPSCs, and primary AMLs with RUNX1mut. RUNX1 binding in model cells and primary AMLs. (A) Heat map of RUNX1mut-binding sites in RUNX1mut-transduced CB cells, control and RUNX1mut-induced iPSCs, and primary AMLs with RUNX1mut. (B) Screenshot of RUNX1 binding in CB-RUNX1mut and control cells, iPSC-RUNX1mut cells with and without dox, and primary AMLs expressing RUNX1mut. (C) Differential expression of genes that are bound by RUNX1 in both RUNX1wt and RUNX1mut AMLs. NUCB2 (left) is higher expressed in RUNX1wt AMLs, whereas TAL1 (right) is expressed more in RUNX1mut AMLs. Differential levels of H3K27ac are associated with the levels of expression. (D) Expression levels and levels of DNaseI, H3K27ac, and H3K27me3 at the CTSG locus in RUNX1wt vs RUNX1mut AMLs. (E) Expression levels and levels of DNaseI, H3K27ac, and H3K27me3 at the CEBPA locus in RUNX1wt vs RUNX1mut AMLs. Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology

RUNX1mut vs AML1-ETO. RUNX1mut vs AML1-ETO. (A) Genomic distribution of RUNX1mut, AML1-ETO, and AML1-EVI1 binding sites. All peaks are assigned to promoters (2 kb away from TSS), exons, introns, and intergenic regions based on the physical distance. The priority rule of category assignment: promoter > exon > intron > intergenic region. (B) Gene overlap of RUNX1mut, AML1-ETO, and AML1-EVI1 binding sites selected by +5 kb, −1 kb distance. (C) Differential expression of RUNX1mut and AML1-ETO iPSC. Several significant genes regulated by RUNX1 or AML1-ETO are highlighted. (D) Differential binding of RUNX1 in RUNX1mut and AML1-ETO primary AML samples. (E) Differential expression between 4 RUNX1mut AMLs and 3 AML1-ETO AMLs. (F) Biological processes enriched for genes upregulated in RUNX1mut AMLs compared with AML1-ETO AMLs. Mylène Gerritsen et al. Blood Adv 2019;3:320-332 © 2019 by The American Society of Hematology